$ja7P# h1 B XL+5bLw `RPV^q]-cV$ #Wc ! M;}p_ QhZkj\4Wg ,zV-mN-3qVqm Ux/F +[V`]+G+[ 3u C4M45 Q_g$ _@w}xD@(w_@n_}|}l_T j&L&Q ,|L;O~, TIGbCSxIErx HBbiB]d1Bi]1HH 1SbR)p/S0?/ 7S-bS5zz qhGG?7GG_. JzI :k-3Pg- CW V1K 7Yy o?k[E gOg}-!_! BQ CvF4 Pn]Ae h1| 9;TsT~bTY Zc z3RF D\qm% (h;.
Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/,1i(mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.